Deng Daling, Zhang Tianhao, Ma Lulin, Zhao Wenjing, Huang Shiqian, Wang Kaixing, Shu Shaofang, Chen Xiangdong
Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China.
Key Laboratory of Anesthesiology and Resuscitation, Huazhong University of Science and Technology, Ministry of Education, Wuhan, China.
Cell Biosci. 2024 Apr 20;14(1):51. doi: 10.1186/s13578-024-01227-3.
Pain is a common symptom of many diseases with a high incidence rate. Clinically, drug treatment, as the main method to relieve pain at present, is often accompanied by different degrees of adverse reactions. Therefore, it is urgent to gain a profound understanding of the pain mechanisms in order to develop advantageous analgesic targets. The PD-L1/PD-1 pathway, an important inhibitory molecule in the immune system, has taken part in regulating neuroinflammation and immune response. Accumulating evidence indicates that the PD-L1/PD-1 pathway is aberrantly activated in various pain models. And blocking PD-L1/PD-1 pathway will aggravate pain behaviors. This review aims to summarize the emerging evidence on the role of the PD-L1/PD-1 pathway in alleviating pain and provide an overview of the mechanisms involved in pain resolution, including the regulation of macrophages, microglia, T cells, as well as nociceptor neurons. However, its underlying mechanism still needs to be further elucidated in the future. In conclusion, despite more deep researches are needed, these pioneering studies indicate that PD-L1/PD-1 may be a potential neuroimmune target for pain relief.
疼痛是许多疾病的常见症状,发病率很高。临床上,药物治疗作为目前缓解疼痛的主要方法,常常伴随着不同程度的不良反应。因此,迫切需要深入了解疼痛机制,以开发有利的镇痛靶点。PD-L1/PD-1通路是免疫系统中的一种重要抑制分子,参与调节神经炎症和免疫反应。越来越多的证据表明,PD-L1/PD-1通路在各种疼痛模型中被异常激活。阻断PD-L1/PD-1通路会加重疼痛行为。本综述旨在总结关于PD-L1/PD-1通路在缓解疼痛中作用的新证据,并概述疼痛缓解所涉及的机制,包括巨噬细胞、小胶质细胞、T细胞以及伤害性感受器神经元的调节。然而,其潜在机制仍需在未来进一步阐明。总之,尽管还需要更深入的研究,但这些开创性的研究表明,PD-L1/PD-1可能是缓解疼痛的潜在神经免疫靶点。
Cell Biosci. 2024-4-20
CNS Neurosci Ther. 2022-1
Int J Physiol Pathophysiol Pharmacol. 2015-8-15
Pharmacol Ther. 2023-8
J Mol Med (Berl). 2025-1
Front Oncol. 2023-10-24
Int Immunopharmacol. 2023-3